Русский
Combination therapy in the management of urinary disorders after transurethral resection of the prostate
DOI: https://dx.doi.org/10.18565/urology.2018.1.62-70
D.V. Ergakov, A.G. Martov
D.D. Pletnev City Clinical Hospital, (Head Physician – Ph.D., I.A. Nazarova), Moscow Health Department, Moscow, Russia; Department of Urology (Head – Dr.Med.Sci., Prof. A.G. Martov), IPPE of A.I. Burnazyan SSC Federal Medical Biophysical Center of FMBA of Russia, Moscow, Russia
Introduction. Surgery in patients with large prostates due to benign prostatic hyperplasia (BPH) results in severe dysuria manifesting as frequent or urgent need to urinate and urinary incontinence. Traditionally, these conditions are treated with alpha blockers. Recently, alpha-blockers and the anticholinergic combination have been used showing additional advantages. This study aimed to investigate the comparative effectiveness of monotherapy versus combination therapy in the treatment of postoperative dysuria in BPH patients with large prostates undergoing transurethral surgery.
Materials and methods. From September 2016 to March 2017, 94 BPH patients with prostates greater than 100 cc underwent transurethral surgery at the Department of Urology of D.D. Pletnev Clinical Hospital; 22 patients had exclusion criteria. In the postoperative period, 36 patients received 0.4 mg of modified release tamsulosin (Omnik®) for a month, and 36 patients were administered controlled release tablets tamsulosin 0.4 mg + solifenacin 6 mg (Vezomni®) as fixed-dose combination therapy. At one month postoperatively, patients were asked to rate their symptoms on a visual analogue scale and fill out I-PSS and QoL questionnaires. Preoperative parameters of the groups were: visual analogue scale scores were 5.1 and 5.2, I-PSS scores were 24 and 24.2, QoL scores were 4.5 in both groups. Prostate volumes were 114 and 118 cc; maximum urinary flow rates were 7.7 vs. 7.5 ml/sec, residual urine volumes were 110 vs. 105 ml, respectively.
Results. Visual analogue scale scores were 6.5 versus 9.2 points, I-PSS scores were 16.3 versus 12.1. The patients of the second group had greater mean micturition volume (150 versus 240 ml); other variables did not differ statistically significantly between the groups. Adverse reactions were mild, and drugs were not discontinued in any case.
Conclusion. In BPH patients with dysuria after transurethral resection of large prostates, Vezomni® administration results in a better quality of life due to an improvement in urgency and nocturia.
Materials and methods. From September 2016 to March 2017, 94 BPH patients with prostates greater than 100 cc underwent transurethral surgery at the Department of Urology of D.D. Pletnev Clinical Hospital; 22 patients had exclusion criteria. In the postoperative period, 36 patients received 0.4 mg of modified release tamsulosin (Omnik®) for a month, and 36 patients were administered controlled release tablets tamsulosin 0.4 mg + solifenacin 6 mg (Vezomni®) as fixed-dose combination therapy. At one month postoperatively, patients were asked to rate their symptoms on a visual analogue scale and fill out I-PSS and QoL questionnaires. Preoperative parameters of the groups were: visual analogue scale scores were 5.1 and 5.2, I-PSS scores were 24 and 24.2, QoL scores were 4.5 in both groups. Prostate volumes were 114 and 118 cc; maximum urinary flow rates were 7.7 vs. 7.5 ml/sec, residual urine volumes were 110 vs. 105 ml, respectively.
Results. Visual analogue scale scores were 6.5 versus 9.2 points, I-PSS scores were 16.3 versus 12.1. The patients of the second group had greater mean micturition volume (150 versus 240 ml); other variables did not differ statistically significantly between the groups. Adverse reactions were mild, and drugs were not discontinued in any case.
Conclusion. In BPH patients with dysuria after transurethral resection of large prostates, Vezomni® administration results in a better quality of life due to an improvement in urgency and nocturia.
Keywords: tamsulosin, solifenacin, benign prostatic hyperplasia, transurethral resection of the prostate
About the Autors
Corresponding author: A.G. Martov – Dr.Med.Sci., Prof., Head of Department of Minimally Invasive Methods of Diagnosis and Treatment of Urologic Diseases "MMDiL", D.D. Pletnev CCH, Moscow HD; Head of Department of Urology and Andrology, IPPE of A.I. Burnazyan SSC FMBC, FMBA of Russia, Moscow, Russia; e-mail: martovalex@mail.ru
